Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Martin, Petra, Noonan, Sinead, Mullen, Michael P, Scaife, Caitriona, Tosetto, Miriam, Nolan, Blathnaid, Wynne, Kieran, Hyland, John, Sheahan, Kieran, Elia, Giuliano, O’Donoghue, Diarmuid, Fennelly, David, O’Sullivan, Jacintha
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4289341/
https://ncbi.nlm.nih.gov/pubmed/25428203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-887
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados